By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and ...

Robert Kennedy Jr. signs recommendation eliminating mercury-based thimerosal from influenza vaccines, fulfilling anti-vaccine advocacy despite FDA safety data.

COVID is once again climbing to troubling levels in California — a worrying trend as health officials attempt to navigate a ...

Those with private health insurance expected to have an easier time getting vaccines than those on Medi-Cal if CDC changes ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

U.S. suspends Ixchiq vaccine license due to serious side effects, raising concerns over chikungunya virus spread globally.

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...